Literature DB >> 28209299

Classic cytotoxic drugs: a narrow path for regulatory approval.

Xavier Pivot1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28209299     DOI： 10.1016/S1470-2045(17)30089-X

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  1 in total

1.  Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine.

Authors:  Xavier Pivot; Seock Ah Im; Matthew Guo; Frederik Marmé
Journal:  Breast Cancer       Date:  2018-01-04       Impact factor: 4.239
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.